

Lentiviral-mediated gene therapy for mucopolysaccharidosis type IIIA

Chantelle McIntyre

Discipline of Paediatrics

School of Paediatrics and Reproductive Health

Faculty of Health Sciences

The University of Adelaide

Submitted August 2014

Contents

1	Abstract.....	14
2	Declaration.....	17
3	Acknowledgments	18
1	Introduction	20
1.1	Inborn errors of metabolism.....	20
1.2	Lysosomal storage disorders.....	21
1.2.1	Complex pathologies	24
1.2.1.1	Ultrastructural features	24
1.2.1.2	Impairment of autophagy	25
1.2.1.3	Immune system irregularities	26
1.2.1.4	Altered energy balance	30
1.3	The mucopolysaccharidoses	30
1.3.1	Mucopolysaccharidosis type III (MPS III)	32
1.3.2	Mucopolysaccharidosis type IIIA (MPS IIIA)	33
1.3.2.1	Incidence and clinical features.....	33
1.3.2.2	Heparan sulphate	34
1.3.2.3	Sulphamidase	38
1.3.2.4	The MPS IIIA mouse model	39
1.3.2.5	Treatment strategies for the MPS.....	41
1.4	Gene therapy.....	49
1.4.1	Viruses as gene therapy vectors	51
1.4.1.1	Adenoviral vectors	51
1.4.1.2	Adeno-associated viral vectors	53

1.4.1.3	Retroviral vectors	56
1.4.2	Human immunodeficiency virus type I (HIV-I).....	63
1.4.2.1	HIV-1 genome organization and virion structure.....	63
1.4.2.2	The HIV-1 replication cycle.....	67
1.4.2.3	HIV-1 derived vectors for gene therapy	70
1.5	Lentiviral-mediated gene therapy for MPS IIIA	74
2	Materials and methods.....	76
2.1	Materials	76
2.1.1	Tissue culture	76
2.1.1.1	Cell lines	76
2.1.1.2	Materials	76
2.1.2	Bacterial strains and media	77
2.1.3	Solutions and buffers	78
2.1.4	Real time PCR reagents and consumables.....	79
2.1.4.1	Materials	79
2.1.4.2	Primers and probes	80
2.1.5	Commercial kits	80
2.1.6	Materials and equipment used in studies involving live animals.....	81
2.1.6.1	Materials	81
2.1.6.2	Stereotaxic injection equipment.....	82
2.1.7	Other chemicals, reagents and consumables.....	82
2.1.8	Transfer vectors and helper plasmids (schematic maps)	88
2.1.8.1	Transfer vectors	88

2.1.8.2	Helper plasmids.....	90
2.1.9	Oligonucleotides for codon optimized murine sulphamidase	92
2.1.9.1	Forward primers.....	92
2.1.9.2	Reverse primers	94
2.2	Methods	96
2.2.1	Molecular biology techniques	96
2.2.1.1	Agarose gel electrophoresis.....	96
2.2.1.2	Phenol/chloroform extraction and ethanol precipitation of DNA.....	96
2.2.1.3	Determination of DNA concentration.....	97
2.2.1.4	Polymerase chain reaction.....	97
2.2.1.5	Restriction enzyme DNA digests	98
2.2.1.6	Klenow DNA extension.....	98
2.2.1.7	Alkaline phosphatase dephosphorylation.....	98
2.2.1.8	DNA purification from an agarose gel.....	98
2.2.1.9	Ligations	99
2.2.1.10	DNA sequencing.....	99
2.2.1.11	cDNA synthesis.....	100
2.2.1.12	Preparation of competent E. coli	100
2.2.1.13	Transformation of competent E. coli	102
2.2.1.14	Purification of plasmid DNA	103
2.2.1.15	Construction of an optimised sulphamidase expression vector	104
2.2.2	Cell culture techniques	108
2.2.2.1	Maintenance of cell lines	108
2.2.2.2	Large scale lentivirus production	109
2.2.2.3	Medium scale lentivirus production	113
2.2.2.4	Small scale lentivirus production	115
2.2.2.5	Small scale lentivirus transduction.....	116
2.2.2.6	Lentivirus titer determination by real time PCR	116
2.2.2.7	Assay for replication competent retrovirus and viral p24	117
2.2.2.8	Preparation of cell lysates.....	118

2.2.3	<i>In vivo</i> techniques	119
2.2.3.1	Animals.....	119
2.2.3.2	Breeding	121
2.2.3.3	Toe tagging.....	121
2.2.3.4	Genotyping.....	123
2.2.3.5	Intravenous administration of lentivirus to mice.....	124
2.2.3.6	Intracerebroventricular administration of lentivirus to mice	124
2.2.3.7	Behaviour studies.....	125
2.2.4	Post-mortem analyses	129
2.2.4.1	Sample collection	129
2.2.4.2	β -gal staining of mouse tissue.....	129
2.2.4.3	Isolation of genomic DNA from mouse tissue homogenates	130
2.2.4.4	Real time PCR	130
2.2.4.5	Total protein determination	131
2.2.4.6	Purification of glycosaminoglycans	131
2.2.4.7	Quantification of uronic acid.....	132
2.2.4.8	Gradient poly acrylamide gel electrophoresis (gradient-PAGE)	132
2.2.4.9	Enzyme activity assays	133
2.2.4.10	Isolation of brain gangliosides.....	135
2.2.4.11	Preparation of samples for mass spectrometry (PMP derivatisation).....	136
2.2.4.12	Histology.....	137
2.2.4.13	Statistical analysis	138
3	Study number one: Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.....	140
3.1	Synopsis.....	144
3.2	Introduction	146
3.3	Materials and methods	149
3.3.1	Animals and gene delivery.....	149

3.3.2	Real time PCR analysis	149
3.3.3	Sulphamidase and β -hexosaminidase activity.....	150
3.3.4	Uronic acid assay	150
3.3.5	Preparation of samples for electrospray ionization tandem mass spectrometry (ESI-MS/MS).....	150
3.3.6	Light microscopy	151
3.3.7	Statistical analysis	151
3.4	Results	152
3.4.1	Vector biodistribution and copy number measured by real-time PCR	152
3.4.2	Analysis of sulphamidase and β -hexosaminidase expression	152
3.4.3	Total uronic acid	153
3.4.4	Quantification of HNS-UA	153
3.4.5	Visual analysis of pathology.....	154
3.5	Discussion.....	164
3.6	Acknowledgements.....	168
3.7	References.....	169
4	Study number two: Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer	173
4.1	Abstract	176
4.2	Introduction	178
4.3	Materials and methods	182

4.3.1	Vector construction and production	182
4.3.2	Animals and gene delivery.....	182
4.3.3	Real-time PCR analysis.....	184
4.3.4	Sulphamidase and β -hex activity	184
4.3.5	Purification of gags	185
4.3.6	Analysis of urinary gags	185
4.3.7	Uronic acid assay	185
4.3.8	Open field activity.....	186
4.3.9	Histology	186
4.3.10	Statistical analysis	186
4.4	Results	187
4.4.1	Vector quantification in tissues	187
4.4.1.1	Intravenously treated animals	187
4.4.1.2	Intraventricularly treated animals	187
4.4.2	Sulphamidase activity in mouse tissues	188
4.4.3	β -hex activity in mouse tissues.....	189
4.4.4	Gross anatomical features	190
4.4.5	Analysis of urinary gags	191
4.4.6	Quantification of uronic acid in mouse tissues	191
4.4.7	Behaviour analyses	192
4.4.7.1	Open-field testing.....	192

4.4.8	Histological features	193
4.5	Discussion.....	207
4.6	Acknowledgements.....	212
4.7	References.....	213
5	Study number 3: Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.....	219
5.1	Abstract	222
5.2	Introduction	224
5.3	Methods	230
5.3.1	Vector construction and production	230
5.3.2	Animals and gene delivery.....	231
5.3.3	Behaviour analyses	232
5.3.4	Preparation of fresh tissue	232
5.3.5	Real-time polymerase chain reaction (PCR) analysis.....	233
5.3.6	Sulphamidase and β -hexosaminidase activity.....	233
5.3.7	Ganglioside quantification	234
5.3.8	Histology	234
5.3.9	Statistical analyses	235
5.4	Results	236
5.4.1	Gross anatomical features	236
5.4.2	Vector quantification in tissues	236

5.4.3	Sulphamidase activity in mouse tissues	237
5.4.4	β -hexosaminidase activity in mouse tissues.....	238
5.4.5	G _{M2} and G _{M3} gangliosides in mouse tissues.....	239
5.4.6	Histology	239
5.4.7	Behaviour analyses	241
5.5	Discussion.....	252
5.6	Acknowledgements.....	262
5.7	References.....	263
6	Optimization of lentiviral-mediated gene therapy for murine MPS IIIA (preliminary work and unpublished data).....	276
6.1	Optimisation of the sulphamidase expression vector	277
6.1.1	Introduction	277
6.1.2	Experimental procedure	278
6.1.3	Results.....	279
6.1.4	Discussion and conclusions.....	286
6.2	Comparison of VSV-G and GP64 pseudotyped lentiviruses <i>in vivo</i>	289
6.2.1	Introduction	289
6.2.2	Experimental procedure	290
6.2.3	Results.....	291
6.2.4	Discussion and conclusions.....	295
6.3	Evaluation of a liposome pre-treatment for intravenous gene transfer	297

6.3.1	Introduction	297
6.3.2	Experimental procedure	298
6.3.3	Outcomes of liposome pre-treatment on <i>in vivo</i> gene transfer	298
6.3.4	Discussion and conclusions.....	302
6.4	Optimisation of intracerebroventricular gene delivery	304
6.4.1	Introduction	304
6.4.2	Intracerebroventricular delivery of Indian ink.....	305
6.4.3	Intracerebroventricular delivery of a lentivirus expressing LacZ	307
6.4.3.1	Optimisation of rates and volumes.....	307
6.4.3.2	Vector biodistribution	310
6.4.3.3	Immune system responses.....	317
6.4.4	Discussion and conclusions.....	321
7	Final discussion and conclusions	323
	Bibliography.....	333
	Figure 1-1 Electron micrograph of lysosomal distension within a liver Kupffer cell.....	23
	Figure 1-2 Main functions of the lysosome and their relationship with key cellular processes	23
	Figure 1-3 Carbohydrate composition of heparan sulphate	35
	Figure 1-4 The many roles of heparan sulphate glycoproteins in cells and tissues.....	36
	Figure 1-5 Stepwise degradation of heparan sulphate	37
	Figure 1-6 Proviral genomes of MLV, an oncogenic retrovirus, and HIV, a lentivirus.....	66
	Figure 1-7 Schematic representation of a mature HIV-1 particle	66

Figure 1-8 Schematic representation of the HIV-1 lifecycle.....	69
Figure 1-9 Schematic representation of the vector and helper constructs of the WCH HIV-1 vector system.....	73
Figure 2-1 pHIV-1PGKmSulph	88
Figure 2-2 pHIV-1EF1 α COmSulph-F2A-SUMF1-PRE	89
Figure 2-3 pHIV-1EF1 α COmSulph-CITE-mSUMF1.....	89
Figure 2-4 HIV-1MPSVnlsLacZ.....	90
Figure 2-5 pcDNATat101ml.....	90
Figure 2-6 pHCMVRevmlwhvpre	91
Figure 2-7 pHCMVgagpolmllstwhv	91
Figure 2-8 pHCMV-G	92
Figure 2-9 HIV-1EF1 α COmSulph showing restriction enzyme sites used for cloning	106
Figure 2-10 QuixStand system set-up for large scale concentration and purification of lentivirus	112
Figure 2-11 Medium scale lentivirus purification set-up.....	114
Figure 2-12 Wild-type and MPS IIIA mice	120
Figure 2-13 Mouse toe tagging identification system	122
Figure 2-14 Open field activity grid	126
Figure 2-15 Water cross-maze set-up.....	128
Figure 3-1 Bio-distribution of the sulphamidase lentiviral vector after intravenous delivery to MPS IIIA mice.....	157
Figure 3-2 β -hexosaminidase activity in mouse tissues	158
Figure 3-3 Total uronic acid in mouse tissues.....	159
Figure 3-4 Relative level of HNS-UA in mouse brain	160
Figure 3-5 Morphological assessment of lysosomal storage.....	161

Figure 3-6 Morphological assessment of lysosomal storage within the CNS.....	163
Figure 4-1 Vector copy number	195
Figure 4-2 Sulphamidase activity	196
Figure 4-3 β -hexosaminidase activity in somatic tissues.....	197
Figure 4-4 β -hexosaminidase activity in brain sections after intraventricular administration of vector	198
Figure 4-5 Bladder volumes at necropsy	199
Figure 4-6 Liver weight	200
Figure 4-7 Analysis of urinary gags	201
Figure 4-8 Tissue and urine uronic acid content	202
Figure 4-9 Open-field activity	203
Figure 4-10 Histological features of somatic tissues	204
Figure 4-11 Histological features of the CNS	206
Figure 5-1 Body weight, and liver weight and bladder volume as a percentage of body weight	244
Figure 5-2 Sulphamidase activity in brain sections	245
Figure 5-3 β -hex activity in brain sections and eyes.....	246
Figure 5-4 GM2 and GM3 Gangliosides	247
Figure 5-5 Histology	248
Figure 5-6 Water cross maze (a) and open field activity (b).....	250
Figure 6-1 Enzyme expression from modified sulphamidase vectors in HEK 293T cells.....	282
Figure 6-2 Enzyme expression from modified sulphamidase vectors in NIH 3T3 cells	283
Figure 6-3 Sulphamidase expression in mouse liver	284
Figure 6-4 Comparison of enzyme expression from sulphamidase vectors in 293T cells....	285
Figure 6-5 <i>In vivo</i> transduction by VSV-G and GP64 pseudotyped lentiviral vectors.....	292

Figure 6-6 Real-time PCR detection of VSV-G and GP64pseudotyped lentiviral vector sequences <i>in vivo</i>	294
Figure 6-7 Lentiviral vector copy numbers in tissues from liposome pre-treated, and non-pre-treated, lentivirus treated animals	300
Figure 6-8 β -gal stained liver sections from liposome pre-treated and non-pre-treated lentivirus treated mice.....	301
Figure 6-9 Transverse sections of a mouse brain following intracerebroventricular delivery of Indian ink	306
Figure 6-10 β -gal staining in coronal brain sections following intraventricular infusion of lentivirus expressing lacZ.....	308
Figure 6-11 LacZ positive cells at surfaces associated with the CSF.....	312
Figure 6-12 LacZ lentivirus transduction of neurons and ependyma.....	314
Figure 6-13 LacZ positive cells associated with the hippocampus	316
Figure 6-14 Plasma cell presence in the brains of lentivirus treated mice	319
Table 1-1 Classification of mucopolysaccharidoses.....	31
Table 1-2 Main studies using adeno-associated vectors for MPS gene therapy.....	60
Table 1-3 Main studies using retroviral vectors for MPS gene therapy	61
Table 1-4 Non-viral gene therapy studies for MPS.....	62
Table 3-1 Sulphamidase activity in mouse tissue homogenates relative to protein	156
Table 5-1 Vector copy number	243

1 Abstract

Gene therapy is promising for the treatment of monogenetic disorders because it aims to restore overall homeostasis, not by treating disease symptoms, but by targeting the fundamental cause of disease. Viral vectors are valuable tools for mediating the transfer of therapeutic genes to target cells, and lentiviral vectors in particular are well suited to this role as they chromosomally integrate, can enter dividing and non-dividing cells, and evoke little or no immune response.

The aim of the current thesis was to evaluate the potential of using lentiviral-mediated gene therapy for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), a heritable lysosomal storage disorder affecting the central nervous system (CNS). The chronic and progressive course of MPS IIIA results from lysosomal accumulation of heparan sulphate (a highly sulphated glycosaminoglycan), secondary to deficiency of the lysosomal hydrolase sulphamidase. Accumulation of heparan sulphate within the cells of the reticulo-endothelial system, the monocyte-macrophage system, and neurons, leads to hepatosplenomegaly and severe, progressive neuropathology in affected children, and ultimately to death at around 15 years of age. There are currently no effective treatments for MPS IIIA patients.

The somatic and CNS aspects of pathology in a mouse model of MPS IIIA were addressed in this study using two separate methods of therapeutic gene delivery; intravenous gene delivery, which directs gene transfer to the liver, and gene delivery to the brain *via* the

cerebral lateral ventricles which utilises the cerebrospinal fluid to achieve gene distribution throughout the brain

After intravenous administration of a self-inactivating lentiviral vector expressing murine sulphamidase to young adult MPS IIIA mice, the livers of treated animals were effectively modified to express high levels of therapeutic sulphamidase. The resultant widespread delivery of enzyme secreted from transduced cells to somatic tissues *via* the peripheral circulation corrected most somatic pathology, furthermore, markers of MPS IIIA pathology within the brains of treated mice were significantly reduced. When liver directed gene therapy was repeated in a second cohort of mice, however, similar benefits to the brain were not observed, presumably because the resulting levels of peripherally circulating enzyme were comparatively low. Although, in common with the first study, somatic pathologies still were corrected. Alternatively, lentivirus delivered to the brains of MPS IIIA mice *via* the cerebral lateral ventricles achieved extensive sulphamidase gene distribution and reduced lysosomal storage throughout the brain. Improvements in behaviour were observed for these animals, as was the complete prevention of pathological urine retention.

The blood-brain-barrier (BBB) limits the transfer of therapeutic enzymes from the blood to the brain, therefore gene therapy approaches to treat CNS pathology in the MPS are to either challenge the BBB with high levels of circulating enzyme, or bypass it altogether, by the direct delivery of therapeutic genes into the brain. While both approaches have advantages for the treatment of MPS IIIA, the results presented for the current thesis

suggest that gene delivery to the brain *via* the cerebral lateral ventricles may, at this stage, be the more practical and efficacious approach to the treatment of CNS pathology in MPS IIIA patients.

2 Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1986.

I also give permission for the digital version of my thesis to be made available on the web, *via* the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

SIGNED: DATE:

3 Acknowledgments

First of all, I would like to thank my supervisor Don Anson for providing me with the opportunity to do this PhD and for providing me with a project that I could take great interest in.

I am also grateful to the many people who have been willing to share their time, technical skills and knowledge with me. In particular I would like to thank my co-supervisor, and head of Matrix Biology, Sharon Byers, and also Ainslie Derrick Roberts, for passing on to me their skills and knowledge regarding the MPS and animal models; Peter Clements, for teaching me HPLC, and for providing the radio-labelled substrate that was essential for my enzyme assays; Enzo Ranieri, for time spent explaining to me the principles of mass spectrometry and for helping me to prepare, run and analyse mass spec samples; Peter Sharp, for sharing with me his knowledge of brain gangliosides; the staff at Adelaide Microscopy, for providing an excellent environment for students to work and learn, but particularly to Lyn Waterhouse and Ruth Williams, who took the time to teach me histological techniques. I would also like to thank the Animal House staff, Lynn Scarmen and Leslie Jenkins-White, for maintaining the animals that were essential to my research.

I would like to acknowledge the people that made the Gene Technology Unit (GTU) a motivating, supportive and enjoyable place to work: Stanley Tan, Edward Wong, Karlea Kremer, Rachel Koldej, SinLay Kang, SuePing Lim, Nigel Farrow and Julie Bielicki, and also Josie De Vuono. I would like to also acknowledge the members of Matrix Biology, not

mentioned above, namely, Matilda Jackson, Nathan Rout-Pitt, Xenia Kaidonis, and Carmen Pyragius, for making Matrix Biology a welcoming place to visit and work, Janice Fletcher for her continual supporting and for encouragement and the staff and students of the WCH Cystic Fibrosis Gene Therapy Research Group, David Parsons, Nigel Farrow, Patricia Cmielewski, Martin Donnelly, Harsha Padmanabhan, Ryan Green and Corinne Reynolds for support and encouragement in the final stages of my thesis preparation.

Finally, thank you to my Mother, my Father, my Step Father, my brother and my grandparents, and also my friends, especially Amy and Henrik, for supporting me and for encouraging me to achieve my goals.